Paul Horstmeier - 06 Dec 2021 Form 4/A - Amendment Insider Report for Health Catalyst, Inc. (HCAT)

Role: Chief Operating Officer
Signature: /s/ Daniel Orenstein, as Attorney-in-Fact
Issuer symbol: HCAT
Transactions as of: 06 Dec 2021
Net transactions value: -$141,636
Form type: 4/A - Amendment
Filing time: 29 Dec 2021, 16:19:29 UTC
Date Of Original Report: 07 Dec 2021
Previous filing: 07 Dec 2021
Next filing: 29 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HCAT	Common Stock	Options Exercise	$96,038	+6,063	+6.1%	$15.84	105,243	06 Dec 2021	Direct	F1
transaction	HCAT	Common Stock	Sale	$22,780	-600	-0.57%	$37.97	104,643	06 Dec 2021	Direct	F2, F3
transaction	HCAT	Common Stock	Sale	$103,644	-2,674	-2.6%	$38.76	101,969	06 Dec 2021	Direct	F2, F4
transaction	HCAT	Common Stock	Sale	$111,250	-2,789	-2.7%	$39.89	99,180	06 Dec 2021	Direct	F2, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HCAT	Stock Option (Right to Buy)	Options Exercise	$0	-6,063	-10%	$0.000000	52,028	06 Dec 2021	Common Stock	6,063	$15.84	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Due to a technical and administrative error, the original Form 4, filed on December 7, 2021, incorrectly reflected a sale of shares of Common Stock by the Reporting Person attributed to a vesting of Restricted Stock Units. We were recently made aware that the Reporting Person exercised options and sold shares from that option exercise. The exercise of those options and sale of shares is correctly reflected herein and the correct ownership tabulations are also included herein.
F2	The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 15, 2020, in accordance with Rule 10b5-1.
F3	Represents the weighted average sale price of the shares sold ranging from $37.47 to $38.43 per share, inclusive.
F4	Represents the weighted average sale price of the shares sold ranging from $38.47 to $39.24 per share, inclusive.
F5	Represents the weighted average sale price of the shares sold ranging from $39.66 to $40.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (3) through (5).
F6	25% of the 186,467 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023.